← Back to Search

Immunomodulator

ABX196 for Hepatocellular Carcinoma

Phase 1 & 2
Recruiting
Led By Darren SIGAL, MD
Research Sponsored by Abivax S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Summary

This trial is testing a new drug, ABX196, to see if it is safe and effective in treating hepatocellular carcinoma when used with nivolumab.

Eligible Conditions
  • Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events (AEs)
Secondary study objectives
Objective Response Rate (ORR)

Trial Design

1Treatment groups
Experimental Treatment
Group I: ABX196Experimental Treatment1 Intervention
IM injection of 0.1, 0.2, and 0.4 µg of ABX196

Find a Location

Who is running the clinical trial?

Abivax S.A.Lead Sponsor
21 Previous Clinical Trials
4,399 Total Patients Enrolled
C3 Research AssociatesUNKNOWN
2 Previous Clinical Trials
111 Total Patients Enrolled
Darren SIGAL, MDPrincipal InvestigatorScripps Clinic/Scripps MD Anderson Cancer Center
~8 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top